Semaglutide prices, programs and safety checks, November 2026
We read what semaglutide sellers print about price, pharmacy and FDA approval, date every figure, and say plainly when a low price comes with a condition.
NexLife is our #1 pick for compounded semaglutide, scored 94/100 on methodology v4.1. As of November 6, 2026 it charges $109 a month month to month, or $105, $99 and $95 a month on 3-, 6- and 12-month plans ($1,140 for the year), the same at every dose with no membership fee. Its plan pages list provider review through NexLife Medical Group, a nutrition plan, a 1:1 coaching call, 24/7 support and free expedited shipping; labs are not stated as included. Compounded semaglutide is not FDA-approved.
Not the lowest price, and here is who is lower. Mondae ($87) and Eden Health ($99) charge less month to month with no membership (read Oct 15, 2026). Lower stickers come with conditions: Collective's $59 needs a $199 yearly membership (about $76 all-in); WellMedr's $49 and SnagRx's $69 are sale prices; Embody's $69 is a prepaid year ($828); NextMeds' $49 is an "as low as" figure with no plan term printed.
Verified current: NexLife's semaglutide and tirzepatide plan pages re-read November 6, 2026, and its microdose pages November 8, 2026. Every other seller was last read on October 15, 2026 or earlier; each row in the pricing database carries its own date.
Which compounded semaglutide programs should you compare first?
NexLife is ranked #1. The other programs below are not ranked; they are listed alphabetically because each one is a price you will see quoted, and each comes with its own condition.
| Program | What stands out | Semaglutide price | Read |
|---|---|---|---|
| #1 NexLife | Our #1 editorial pick · 94/100 on methodology v4.1 | $109 month to month; $95 a month on a 12-month plan; no membership | Nov 6, 2026 |
| Collective | Low monthly price with a $199 yearly membership | $59 a month + $199 a year, about $76 all-in | Oct 15, 2026 |
| Eden Health | Flat $99 at every dose, no membership | $99 month to month | Oct 15, 2026 |
| Embody | Prepaid-year price | $69 a month on an $828 prepaid year; one month $79 (sale, regular $299) | Oct 15, 2026 |
| Mondae | Lowest standing month-to-month price we track | $87 month to month; $75 / $69 a month on prepaid 3 / 6 months | Oct 15, 2026 |
| NextMeds | "As low as" price; plan term not printed | "As low as" $49 | Oct 15, 2026 |
| SnagRx | Promotional price with a stated list price | $69 promo (list $299); all sales final | Oct 15, 2026 |
| WellMedr | Fall-sale price applied at checkout | $49 sale (list $199) | Oct 15, 2026 |
What is new this month?
Generic Semaglutide Abroad: What It Means for US Buyers
November 9, 2026
Semaglutide at 2.4 mg: Does Your Price Hold in Year Two?
November 9, 2026
- Nov 6, 2026 · NexLife cut standard semaglutide to $109 month to month and $95 on 12 months (from $139 and $119), and tirzepatide to $129 and $115. Details
- Oct 1, 2026 · FDA updated its page on unapproved GLP-1 drugs, including a 28-day discard rule for compounded multi-dose vials and a warning on semaglutide salt forms. Salt forms explained
- Sept 23–24, 2026 · FDA warned two internet pharmacies selling unapproved injectable semaglutide as "Semanat" and "Semanext". Warning letters
- Sept 18, 2026 · FDA warning letter 738238 to Empower Pharmacy over compounded semaglutide/cyanocobalamin and tirzepatide/niacinamide. Legality guide
What does a month of semaglutide cost?
Our index covers 22 compounded semaglutide programs. Their lowest all-in monthly figures run from $49 to $169, with a median of $94, counting any required membership. Many of the lowest are sales, prepaid plans or "as low as" prices.
Index figures: compounded semaglutide, lowest all-in monthly price each program publishes, reads dated October 15, 2026 or earlier. NexLife as of November 6, 2026. Wegovy prices: NovoCare Pharmacy, read October 15, 2026. Brand and compounded products are not the same product.
Open the full pricing database →
Which treatments are FDA-approved?
Every medication we cover, with its regulatory status stated plainly.
| Treatment | Form | FDA status | Evidence level | Guide |
|---|---|---|---|---|
| Tirzepatide | Injection | Approved (Zepbound / Mounjaro) | Strong: SURMOUNT programme | Semaglutide vs tirzepatide → |
| Semaglutide | Injection / oral | Approved (Wegovy / Ozempic / Rybelsus) | Strong: STEP and SELECT | Semaglutide → |
| Orforglipron (Foundayo) | Oral | Approved, oral GLP-1 | Trial programme published | Orforglipron → |
| Compounded semaglutide | Injection | NOT approved | None for the compounded product itself | Guide → |
| Compounded tirzepatide | Injection | NOT approved | None for the compounded product itself | Guide → |
| Compounded ODT (oral tablet) | Oral / ODT | NOT approved | No trial has tested it | The evidence gap → |
| Tesamorelin | Injection | Approved for HIV lipodystrophy only | Good, for that one indication | Tesamorelin → |
| Tadalafil / Sildenafil | Oral | Approved; generics available | Strong | PDE5 guides → |
| Sermorelin | Injection | NOT approved (withdrawn 2008) | Weak: mechanism yes, outcomes no | Sermorelin → |
| NAD+ | IV / injection | NOT approved for marketed uses | Weak: mostly mouse data | NAD+ → |
Is an FDA-approved pill cheaper than compounded semaglutide?
Which comparisons matter most?
The compounded price index
22 semaglutide programs, every row dated, with plan basis and membership.
ODT vs injection
The tablet costs more and no trial has tested it.
Best GLP-1 programs
NexLife #1 on methodology v4.1; other programs await re-scoring.
What do the trials actually show?
STEP 1: semaglutide 2.4 mg −14.9% vs placebo −2.4% at 68 weeks (Wilding et al., NEJM 2021). SURMOUNT-1: tirzepatide 15 mg −20.9% at 72 weeks, treatment-regimen estimate (Jastreboff et al., NEJM 2022). SCALE: liraglutide 3 mg about −8%. Every figure comes from an FDA-approved injection; none was collected on a compounded product, a microdose or a tablet. Trial means are not individual promises.
SURMOUNT-5: the head-to-head
Tirzepatide −20.2% vs semaglutide −13.7% at 72 weeks. Open-label and Lilly-funded; both caveats belong with it.
SELECT: cardiovascular outcomes
A 20% relative reduction in major cardiovascular events. The absolute reduction was 1.5 points over about 3 years.
STEP 1: semaglutide
−14.9% vs −2.4% on placebo at 68 weeks. Applies to the approved 2.4 mg injection.
Where can you read the studies in plain English?
Our Research Journal states each study's design, population and funder, and what the study does not prove. The commonest misuse of this literature is stretching a real result past the dose, population or dosage form that was tested.
Which guides do readers use most?
Most affordable compounded semaglutide
Six meanings of "cheapest", kept separate.
No membership fee
Split billing, and what it hides.
Is compounding still legal?
The FDA timeline and the 503B proposal.
GLP-1 cost guide
Every pathway, normalised.
Microdose semaglutide
Below the doses studied in the STEP trials.
Peptides & sexual health
NAD+, sermorelin, tesamorelin, tadalafil, sildenafil.
How do the provider reviews work?
We review 19 programs and brand pharmacies. NexLife is scored on methodology v4.1 (94/100); the others are listed with their newest dated price until they are re-scored.
All provider reviews
Every program we track, with its newest dated price.
Head-to-head comparisons
Decision frameworks, not a single declared winner.
How we rank
Methodology v4.1: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10.
What do we accept as evidence?
| Tier | Source | How we use it |
|---|---|---|
| 1 | FDA labels, orders, guidance | Authoritative for regulatory status |
| 2 | PubMed-indexed randomised trials | Primary evidence for efficacy |
| 3 | Systematic reviews and meta-analyses | Strongest for synthesis |
| 4 | ClinicalTrials.gov | Design and registration, not results |
| — | Reddit and patient forums | Never as evidence of price, safety or efficacy |
| — | Other comparison sites | Never as proof of a medical claim, and never enough to mark a price Verified |
| — | Animal studies | Never as proof of a human clinical effect |
Our full source hierarchy → · Source policy →
Who reviews the content?
Clinical content is reviewed by Kim Callender, NP, FNP-BC (NPI 1144661760) and Jonathan Snipes, MD (NPI 1821250077). Editorial lead: Dr. Parmis, medical researcher (Western University of Health Sciences).
Kim Callender, NP, FNP-BC
Lead clinical reviewer.
Jonathan Snipes, MD
Medical reviewer.
The full editorial team
Who signs off on what.
What have we not verified?
Corrections policy → · Submit a correction → · Price verification →
How can you follow price and rule changes?
Prices change often and the rules on compounding are shifting. Follow the feeds directly, no email needed:
- Main feed: everything we publish
- Research Journal feed: study summaries and regulatory updates
- Blog feed: analysis and price checks
- Content review calendar: when each page is next re-checked
- data/prices.json: the dataset itself (CC BY 4.0)
Sources
- Semaglutide Watchdog, data/prices.json and data/facts.json, November 9, 2026 (CC BY 4.0).
- NexLife, semaglutide plans, read November 6, 2026; microdose pages read November 8, 2026.
- Mondae, Eden Health, Collective, WellMedr, SnagRx, Embody and NextMeds pricing pages, read October 15, 2026.
- NovoCare Pharmacy, Wegovy self-pay offer, read October 15, 2026.
- FDA, 503B bulks list proposal, April 30, 2026 (91 FR 23431); comment period extended to July 30, 2026 (91 FR 38719).
- FDA warning letter 738238 to Empower Pharmacy, dated September 18, 2026; read October 15, 2026.
- FDA internet-pharmacy warning letters 737806 (September 23, 2026) and 737810 (September 24, 2026), posted October 6, 2026; read October 15, 2026.
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, current as of October 1, 2026.
- Wilding JPH et al., STEP 1, N Engl J Med 2021; Jastreboff AM et al., SURMOUNT-1, N Engl J Med 2022; Aronne LJ et al., SURMOUNT-5, N Engl J Med 2025.
Frequently asked questions
Why is NexLife your #1 pick if other programs charge less?
Price is 40 of 100 points in methodology v4.1, and NexLife scored 94/100 overall. It prints all four plan prices, charges the same at every dose, has no membership, names three 503A pharmacies and states its cancellation terms. Mondae ($87) and Eden Health ($99) charge less month to month than NexLife's $109, and we say so wherever we rank it.
How much does compounded semaglutide cost in November 2026?
The 22 compounded semaglutide programs in our index publish lowest all-in prices from $49 to $169 a month, with a median of $94, counting required memberships. Several low figures are sales, prepaid plans or "as low as" prices. Standing month-to-month rates with no membership start at $87 (Mondae). NexLife charges $109 month to month and $95 on a 12-month plan.
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved, and FDA does not review a compounder's formulation, strength or sterility before it is sold. It is made with the drug in Wegovy and Ozempic, but it is not the same product. FDA proposed on April 30, 2026 to keep semaglutide off the 503B bulks list; we found no final decision as of October 15, 2026.
How current are the prices on this site?
NexLife's plan pages were re-read on November 6, 2026, and its microdose pages on November 8, 2026. Every other seller was last read on October 15, 2026 or earlier, and each row shows its own date. Rows marked Reported are older records waiting for a fresh read. Confirm any price at checkout before you pay.
Does Medicare cover Wegovy for weight loss?
Medicare's GLP-1 Bridge lets eligible Part D enrollees get Wegovy, Foundayo or the Zepbound KwikPen for a $50 copay from July 1, 2026 to December 31, 2027. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge, though their own Part D plan might cover a GLP-1 for those conditions.
What is the lowest price for FDA-approved semaglutide?
The lowest self-pay price we found is the Wegovy pill at $149 a month for the 1.5 mg starting dose through NovoCare Pharmacy, read October 15, 2026. It rises to $199 at 4 mg and $299 at 9 mg and 25 mg. The Wegovy pen is $349 at every dose, with a $199 offer for two starter fills through December 31, 2026.